Please use this identifier to cite or link to this item:
Title: The first but not the second thrombospondin type 1 repeat of ADAMTS5 functions as an angiogenesis inhibitor
Authors: Sharghi-Namini, S. 
Fan, H. 
Sulochana, K.N. 
Potturi, P. 
Xiang, W. 
Chong, Y.-S.
Wang, Z.
Yang, H.
Ge, R. 
Keywords: ADAMTS5
Issue Date: 27-Jun-2008
Citation: Sharghi-Namini, S., Fan, H., Sulochana, K.N., Potturi, P., Xiang, W., Chong, Y.-S., Wang, Z., Yang, H., Ge, R. (2008-06-27). The first but not the second thrombospondin type 1 repeat of ADAMTS5 functions as an angiogenesis inhibitor. Biochemical and Biophysical Research Communications 371 (2) : 215-219. ScholarBank@NUS Repository.
Abstract: Angiogenesis is critical for tumour growth and metastasis where factors that regulate this process are potential targets for development of anti-cancer drugs. In this study, we show that the first TSR domain of the extracellular matrix protease ADAMTS5, unlike the second TSR, has anti-angiogenic activities where it inhibits endothelial cell tube formation on Matrigel, reduces cell proliferation and attachment, while promoting cell apoptosis and migration, all in a dose-dependent manner. Furthermore, it influences the architecture of endothelial cells by disrupting actin stress fibres and reducing focal adhesions, likely via suppressing RhoA activation. TSR1 of ADAMTS5 is therefore a novel anti-angiogenic peptide and could serve as a prototype for future development into anti-cancer drugs. © 2008 Elsevier Inc. All rights reserved.
Source Title: Biochemical and Biophysical Research Communications
ISSN: 0006291X
DOI: 10.1016/j.bbrc.2008.04.047
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.